Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17789645 | 0.80 | SMN1; SMN2 (0.54) | GAASMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL4432834 | 0.79 | TP53 (0.55) | GAASMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL25831427 | 0.77 | GAA (0.44) | GAASMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL10232853 | 0.76 | TP53 (0.47) | GAASMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL27000160 | 0.75 | SMN1; SMN2 (0.42) | GAASMN1; SMN2TP53ALDH1A1HTT | |
| SCHEMBL10017888 | 0.73 | KDM2B (0.50) | SMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL13676337 | 0.73 | KDM2B (0.50) | SMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL10017896 | 0.73 | KDM2B (0.50) | SMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL20205996 | 0.73 | MAPT (0.56) | GAASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL2433692 | 0.73 | SMN1; SMN2 (0.43) | GAASMN1; SMN2TP53ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | NAAA, PAM, AANAT | GAA 2109/4885SMN1; SMN2 4030/4885TP53 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.